EcoDrugPlus

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSPMAG00000004384
Gene Symbol: FNTA
1 Cross references
221 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSPMAG00000009479
Gene Symbol: FNTB
1 Cross references
210 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSPMAG00000007212
Gene Symbol: FGFR2
1 Cross references
219 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSPMAG00000008966
Gene Symbol: FGFR2
1 Cross references
219 Possible Orthologues:

Folate Receptor

Ensembl ID : ENSPMAG00000004213
Gene Symbol: FOLR
1 Cross references
436 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSPMAG00000002825
Gene Symbol: GLA
1 Cross references
196 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSPMAG00000004383
Gene Symbol: GABBR2
2 Cross references
239 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6a

Ensembl ID : ENSPMAG00000001594
Gene Symbol: GABRA6A
1 Cross references
195 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSPMAG00000002466
Gene Symbol: GABRG2
1 Cross references
213 Possible Orthologues:

Glucokinase (Hexokinase 4)

Ensembl ID : ENSPMAG00000003141
Gene Symbol: GCK
1 Cross references
211 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSPMAG00000005895
Gene Symbol: GBA1
1 Cross references
254 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSPMAG00000004612
Gene Symbol: GRIK1
2 Cross references
176 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).